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ABSTRACT
Background    Musculoskeletal infections are often seen 
in the daily practice of orthopedics. Several markers 
[white blood cell (WBC), C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), procalcitonin 
(PCT)] have been used for diagnosing these infections. 
However, these markers may be elevated due to surgery 
or trauma, and may not be infection-related. These 
markers also show drug-dependent dynamics during 
infection that differ from its usual dynamics. Such situa-
tions make diagnosis of infections difficult, and Cluster 
of Differentiation 64 (CD64) has been brought to atten-
tion. This study aimed to clarify the utility of CD64 on 
neutrophils by comparing it with conventional infection 
markers (CRP, PCT) in musculoskeletal infection. 
Methods    Forty-four patients who were suspected of 
having musculoskeletal infection between May 2010 
and November 2013 in our hospital were enrolled in this 
study. Patients were divided into subgroups according to 
their culture results, antibiotics administration, measure-
ment timing, and if they were immunocompromised. 
The measurements of the infection markers were 
compared between each group. In addition, the positive 
rates of each infection marker were compared between 
groups. 
Results    There was no difference in the infection marker 
measurements between several groups. There was no 
statistically significant difference between groups for the 
positive rates of CD64, CRP, and PCT. 
Conclusion    We evaluated the utility of CD64 on 
neutrophils in musculoskeletal infection. CD64 showed 
the utility that was equivalent to conventional infection 
markers in diagnoses of various musculoskeletal infec-
tions.
Key words    Cluster of Differentiation 64; C-reactive 
protein; musculoskeletal infections; procalcitonin
Musculoskeletal infections are often seen in the daily 
practice of orthopedics. Several markers [white blood 
cell (WBC), C-reactive protein (CRP), erythrocyte sed-
imentation rate (ESR), procalcitonin (PCT)] have been 
used to diagnose these infections, but elevated levels can 
be due to reasons other than infection, for instance sur-
gery or trauma. These markers can also exhibit altered 
drug-dependent dynamics during infection. Such situa-
tions make the diagnosis of infections difficult, and for 
this reason attention has recently been paid to the cluster 
of differentiation 64 (CD64). 
 CD64 is an integral membrane glycoprotein known 
as an Fc receptor, with a molecular weight of 72 kDa. It 
binds monomeric IgG-type antibodies with high affinity 
and is more commonly known as Fc-gamma receptor 1 
(FcγRI). It is constitutively expressed on macrophages, 
monocytes, and eosinophils, but expressed at only low 
levels on normal neutrophils. The expression of CD64 
on neutrophils is upregulated as a physiological response 
to microbial wall components, complement split prod-
ucts, and several cytokines such as interferon-c (IFN-c), 
interleukin-8 (IL-8), IL-12, and granulocyte-colony 
stimulating factor (G-CSF).1–3 Therefore, CD64 may be 
a marker that is specific for infection, and its efficacy in 
the diagnosis of both systemic and local infections has 
been reported.4–6 For the diagnosis of musculoskeletal 
infections seen in orthopedics practice, conventional 
markers such as CRP or PCT may not be effective. In 
particular, in patients with rheumatoid arthritis (RA) it 
is difficult to differentiate between disease activity and 
infection as the cause of the inflammatory reaction. 
CD64 was shown to be useful in this regard, as it is not 
influenced by the disease activity of RA but is increased 
by a variety of bacterial, acid-fast bacilli, viral, and 
fungal infections.4, 7, 8 In the early phase after joint replace-
ment, CD64 helped to differentiate whether elevations in 
other infection markers were due to infection or surgical 
stress.9–11 Furthermore, CD64 was shown to have de-
creased sensitivity for old or local infections.5, 12 However, 
few studies have evaluated the efficacy of CD64 in the 
diagnosis of usual infections that did not occur in the 
context of RA or after joint replacement.12 This study 
aimed to compare neutrophil CD64 expression with 
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conventional infection markers (CRP and PCT) in terms 
of diagnosing musculoskeletal infection in a general 
population of patients.
MATERIALS AND METHODS
Study design
This investigation was a single-facility observational 
study and was approved by the ethics committee of the 
Faculty of Medicine at Tottori University (No.1803). 
Forty-four patients in our hospital who were suspected 
of having musculoskeletal infections between May 2010 
and November 2013 were enrolled in this study. 
 Following the approach of Matsui et al., an infection 
was considered to be present if one of the following 
conditions was met: 1) the presence of a pathogen was 
demonstrated by microbiologic culture or PCR; 2) in-
fection was diagnosed by radiological or other imaging 
findings by at least two physicians; and 3) the patient 
had obvious symptoms of infection or obvious clinical 
effects of treatment with antimicrobial, antiviral, or an-
tifungal agents.4 As followed it, we diagnosed infections 
by positive blood or local cultures. Patients with negative 
cultures were diagnosed after consideration of clinical 
findings (recurrent symptoms, no improvement without 
antibiotics, and infectious inflammation on pathological 
examination). All patients in the blood culture–positive 
group also had same bacteria detected in local cultures, 
and we therefore concluded that there was no contami-
nation in these cases.
 Blood samples (2 mL per patient) were collected 
for routine blood tests and CD64 evaluation using 
EDTA-2K blood collection tubes, and measurements 
were carried out within 2 hours. CD64 expression on 
neutrophils was measured by the following methods 
according to past literature.4 QuantiBrite CD64PE/
CD45PerCP (Beckton Dickinson, San Jose, CA) was 
added to 20 μL to 50 μL of whole blood and incubated 
for 60 minutes in the dark at 20 °C. After erythrocyte 
lysis with Versalysis (Beckman Coulter, Brea, CA) for 
12 minutes, the samples were incubated for an additional 
60 minutes to allow for equilibration and to reduce non-
specific background staining. The expression of CD64 
was examined with a Gallios flow cytometer (Beckman 
Coulter) calibrated using QuantiBrite PE beads (Beckton 
Dickinson). These beads were conjugated with four 
different levels of phycoerythrin (PE), which made it 
possible to create a standard curve for determining the 
mean number of PE molecules present on a cell. The 
mean number of CD64 molecules expressed on the cell 
surface was calculated using the PE fluorescence quan-
tification kit with QuantiBrite PE beads. Three different 
cell populations, namely lymphocytes, monocytes, and 
granulocytes, were identified and gated by their CD45/
side-scatter profile.
 The data are expressed as median and interquartile 
ranges (IQR). The cut-off values were set at 2000 mole-
cules/cell for CD64, 1.0 mg/dL for CRP, and 0.05 ng/mL 
for PCT.13–15
 We assessed the diagnostic utility of CD64 by retro-
spectively analyzing patients with musculoskeletal infec-
tions and evaluating whether CD64 was able to identify 
an infection more accurately than conventional infection 
markers even if the infection had characteristics that 
increased its likelihood of being masked.
 We classified patients by culture results and also 
divided them into subgroups based on the following fac-
tors that contribute to masking of an infection: antibiotic 
administration, late CD64 measurement, and presence of 
an immunodeficient state. First, patients were classified 
based on whether or not they received antibiotics before 
CD64 measurement. Second, they were classified based 
on the timing of CD64 measurement, either within 7 
days of infection onset or afterward. This classification 
was based on a report describing that CD64 expression 
increased within 24 hours after infection onset and 
returned to baseline after 7 days.16 Finally, patients were 
classified based on whether they were immunocom-
promised; immunodeficient patients included diabetes, 
malignant tumor, hepatic failure, renal failure and those 
receiving immunosuppressive drugs such as steroids. 
The positive rates and levels of each infection marker in 
each subgroup were compared and evaluated.
Statistical analysis
Marker measurements were compared using the Mann-
Whitney U test. For culture results, we performed a 
multiplex test using the Steel-Dwass test. The positive 
rate of each infection marker was compared between 
groups by the Fisher’s exact test. A value of P < 0.05 
was considered statistically significant. SPSS Statistics 
Version 24.0 was used for statistical analysis.
RESULTS
Demographic data
Forty-four patients (26 males and 18 females) were 
enrolled in the study. The average age was 62.9 (20–85) 
years. There were 10 cases of surgical-site infection, 
eight of arthritis or osteomyelitis, six of myositis or 
fasciitis, six of perispondylitis, four of cellulitis, four of 
tendinitis or tenosynovitis, three of diabetic gangrene, 
two of skin ulcer infection, and one of bursitis (Table 1).
Cultures
Among the 44 patients, nine had positive blood cultures, 
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21 had positive local cultures, and 14 were negative 
for both. Among patients with positive blood cultures, 
methicillin-sensitive Staphylococcus aureus (MSSA) was 
detected in five cases, Streptococcus pyogenes in two 
cases, and Streptococcus intermedius and Streptococcus 
agalactia in one case each. Among patients with posi-
tive local cultures, MSSA was detected in eight cases, 
methicillin-resistant Staphylococcus aureus in five cases, 
Streptococcus pyogenes in two cases, Pseudomonas 
aeruginosa in two cases, and Streptococcus agalactia, 
Staphylococcus logrunner, and Enterobacter cloacae in 
one case each (Table 2).
 There were no significant differences in age or 
gender between the three culture groups. The median 
(IQR) neutrophil CD64 expression was 12,820 mole-
cules/cell (5,002–18,710) in the patients with positive 
blood cultures, 2,717 molecules/cell (1,341–10,987) in 
those with positive local cultures, and 2,553 molecules/
cell (2,199–3,411) in those with negative cultures. CD64 
expression was significantly higher in patients with 
positive blood cultures than in those with positive local 
cultures. There was no significant difference between 
patients with positive local cultures and those who were 
culture negative (Fig. 1). There were also no significant 
differences in the positive rates of CD64, CRP, or PCT 
between the three groups (Table 3).
Antibiotics
Antibiotics were administered to 22 of the 44 patients 
before marker measurements (Table 4). The median 
neutrophil CD64 expression was 5,400 molecules/
cell (1,463–10,352) in the antibiotic group and 7,765 
molecules/cell (2,340–11,684) in the no-antibiotic group. 
CD64 expression was higher in the former group, but the 
difference was not statistically significant. Antibiotics 
were administered to 15 patients in the positive local 
culture group and to seven in the culture-negative group, 
Table 2. Result of culture and laboratory data of patients
Blood culture (+)     Local culture (+) Culture (–) P* Value
n 9 21 14
CD64 (molecules/cell) 12820 (5002–18710) 2717 (1341–10987.5) 2553 (2199–3411) B:L  < 0.05
L:C  0.761
B:C  < 0.05
CRP (mg/dL) 28.9 (17.24–36.49) 6.31 (2.23–17.13) 4.83 (2.21–13.77) B:L  < 0.05
L:C  0.544
B:C  < 0.05
PCT (ng/mL) 0.5 (0.43–6.75) 0.08 (0.03–1.38) 0.06 (0.03–0.44) B:L  < 0.05
L:C  0.542
B:C  < 0.05
Pathogens (n) MSSA (5) MSSA (8) (–)  
Streptococcus pyogenes (2) MRSA (5)
Streptococcus intermedius (1) Streptococcus pyogenes (2)
Streptococcus agalactiae (1) Pseudomonas aeruginosa (2)
Klebsiella pneumoniae (1)
Streptococcus agalactiae (1)
Staphylococcus lugdunen (1)
Enterobacter cloacae (1)
*Steel-Dwass test
B, Blood culture (+); C, Culture (–); CD64, cluster of differentiation 64; CRP, C-reactive protein; L, Local culture (+); MRSA, 
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PCT, procalcitonin.
Table 1. Clinical and biological data of patients and 
characteristics of infections
Number of patients 44
Age 62.9 (20–85)
Gender
M : F 26 : 18
Diagnosis of infection
SSI : surgical-site infection 10
Arthritis or osteomyelitis 8
Myositis or fascitis 6
Peri-spondylitis 6
Cellulitis 4
Tendinitis or tenosynovitis 4
Diabetic gangrene 3
Infection of skin ulcer 2
Brusitis 1
CD64 (molecules/cell) 6723 ( 701–38640 )
CRP (mg/dL) 13.4 ( 0.1–41.7 )
PCT (ng/mL) 3.1 ( 0–50.3 )
CD64, cluster of differentiation 64; CRP, C-reactive protein; F, 
female; M, male; PCT, procalcitonin.
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P < 0.05 Fig. 1. Neutrophil CD64 expression, CRP, and PCT levels in 
groups with positive blood culture, positive local culture, and 
negative culture. The box shows the 25–75th percentiles, whereas 
the whiskers indicate the 10th and 90th percentiles. N.S. means not 
significant by the Steel-Dwass test. CD64, cluster of differentia-
tion 64; CRP, C-reactive protein; PCT, procalcitonin.
Table 3. Positive rate of each group classified by cul-
ture results
Blood culture (+)
n = 9
Local culture (+)
n = 21
Culture (–)
n = 14 P* Value
CD64
(+) 9 13 12
0.056
(–) 0 8 2
CRP
(+) 9 21 12
0.134
(–) 0 0 2
PCT
(+) 9 14 11
0.163
(–) 0 7 3
*Fisher's exact test
CD64, cluster of differentiation 64; CRP, C-reactive protein; PCT, 
procalcitonin.
but to none in the positive blood culture group. The 
antibiotic and no-antibiotic groups showed no significant 
differences in CD64, CRP, or PCT levels (Fig. 2), and 
the positive rate of each infection marker did not differ 
between the two groups (Table 5).
Timing of CD64 measurement
CD64 was measured within 7 days after infection onset 
in 15 patients, and later than 7 days after onset in 29 
patients (Table 6). Levels of each infection marker were 
significantly higher when measurements were performed 
within 7 days (Fig. 3). The positive rate of CD64 was 
lower within 7 days than afterward, but there was no 
difference in CRP or PCT (Table 7).
Immunodeficiency 
Twenty-three of 44 patients were immunodeficient (Table 8). 
CD64 levels were not significantly different between immuno-
deficient and non-immunodeficient patients (Fig. 4), and there 
were no significant differences between these two groups in 
the positive rate of any of the infection markers (Table 9).
DISCUSSION 
There have been many reports on the efficacy of CD64 
as a diagnostic marker for infection in patients with RA 
and those in the early postoperative period.4, 8–11, 15, 19, 20 
However, the efficacy of CD64 as a diagnostic marker 
for common musculoskeletal infections has not yet been 
examined. Therefore, we measured CD64 expression 
in patients with various musculoskeletal infections in 
a number of different clinical settings, and compared 
its diagnostic utility with that of conventional infection 
markers. 
 Although CD64 has been shown to have good sen-
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Table 4. Clinical details and laboratory data of pa-
tients with and without antibiotics administration
Antibiotics (+) Antibiotics (–) P* Value
n 22 22
Age 61.0 (30–85) 64.7 (20–85)
Gender (n) M (12) M (14)
F (10) F (8)
Culture (n) Blood culture (+) (0) Blood culture (+) (9)
Local culture (+) (15) Local culture (+) (6)
Culture (–) (7) Culture (–) (7)
CD64
(molecules/cell) 3141 (1463–10352) 3896 (2340–11684) 0.301
CRP
(mg/dL) 8.82 (3.13–18.55) 9.35 (2.75–27.45) 0.981
PCT
(ng/mL) 0.17 (0.04–1.8) 0.2 (0.04–0.53) 0.473
*Mann-Whitney U test
CD64, cluster of differentiation 64; CRP, C-reactive protein; F, 
female; M, male; PCT, procalcitonin.
Table 5. Positive rate of each group classified with or 
without antibioticsadministration
Antibiotics (+) Antibiotics (–) P* Value
n = 23 n = 21
CD64
(+) 9 13
0.066
(–) 0 8
CRP
(+) 9 21
1.000
(–) 0 0
PCT
(+) 9 14
0.071
(–) 0 7
*Fisher's exact test
CD64, cluster of differentiation 64; CRP, C-reactive protein; PCT, 
procalcitonin.
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Fig. 2. Neutrophil CD64 expression, CRP, and PCT levels in 
groups with and without antibiotic administration. The box shows 
the 25–75th percentiles, whereas the whiskers indicate the 10th and 
90th percentiles. N.S. means not significant by the Mann-Whitney 
U test. CD64, cluster of differentiation 64; CRP, C-reactive pro-
tein; PCT, procalcitonin.
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Table 6. Clinical details and laboratory data of pa-
tients measured at under or over 7th day after onset
≤ 7th day 7th day < P* Value
n 15 29
Age 65.5 (31–80) 61.6 (20–85)
Gender (n) M (9) M (17)
F (6) F (12)
Culture (n) Blood culture (+) (0) Blood culture (+) (9)
Local culture (+) (15) Local culture (+) (6)
Culture (–) (7) Culture (–) (7)
CD64
(molecules/cell) 10427 (3277–17052) 2589 (1470–4626) < 0.05
CRP
(mg/dL) 18.34 (6.31–34.98) 5.64 (2.56–14.4) < 0.05
PCT
(ng/mL) 0.5 (0.3–3.5) 0.06 (0.03–0.52) < 0.05
*Mann-Whitney U test
CD64, cluster of differentiation 64; CRP, C-reactive protein; F, 
female; M, male; PCT, procalcitonin.
Table 7. Positive rate of each group measured at un-
der or over 7th day after onset
≤ 7th day > 7th day P* Value
n = 15 n = 29
CD64
(+) 15 19
< 0.05
(–) 0 10
CRP
(+) 15 27
0.540
(–) 0 2
PCT
(+) 13 21
0.071
(–) 2 8
*Fisher's exact test
CD64, cluster of differentiation 64; CRP, C-reactive protein; PCT, 
procalcitonin.
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Fig. 3. Neutrophil CD64 expression, CRP, and PCT levels in 
groups defined by the measurement of CD64 within vs. after 7 
days of infection onset. The box shows the 25–75th percentiles, 
whereas the whiskers indicate the 10th and 90th percentiles. N.S. 
means not significant by the Mann-Whitney U test. CD64, cluster 
of differentiation 64; CRP, C-reactive protein; PCT, procalcitonin.
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Table 8. Clinical details and laboratory data of pa-
tients with and without immunodeficiency
Immunodeficiency (+) Immunodeficiency (–) P* Value
n 23 21
Age 69.0 (45–85) 56.2 (20–85)
Gender (n) M (8) M (12)
F (15) F (9)
Culture (n) Blood culture (+) (5) Blood culture (+) (4)
Local culture (+) (8) Local culture (+) (13)
Culture (–) (10) Culture (–) (4)
CD64
(molecules/cell) 3009 (2308–7826) 3828 (1658–11482) 0.991
CRP
(mg/dL) 7.67 (3.33–12.25) 15.93 (2.36–28.04) 0.177
PCT
(ng/mL) 0.11 (0.06–0.63) 0.42 (0.04–2.53) 0.437
*Mann-Whitney U test
CD64, cluster of differentiation 64; CRP, C-reactive protein; F, 
female; M, male; PCT, procalcitonin.
Table 9. Positive rate of each group classified with or 
without immunodeficiency
Immunodeficiency (+) Immunodeficiency (–) P* Value
n = 23 n = 21
CD64
(+) 20 14
0.155
(–) 3 7
CRP
(+) 22 20
1.000
(–) 1 1
PCT
(+) 18 16
1.000
(–) 5 5
*Fisher's exact test
CD64, cluster of differentiation 64; CRP, C-reactive protein; PCT, 
procalcitonin.
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sitivity for the diagnosis of systemic infection, there are 
conflicting results regarding its diagnostic utility in local 
infection.11, 16, 17 When the CD64-positive cut-off level 
was set at 2000 molecules/cell,4 the sensitivity of CD64 
in diagnosing systemic infection was 92.7% and the 
specificity was 96.5%. For local infection, on the other 
hand, the sensitivity was 66.0% and the specificity was 
95.7%.18 In our study, CD64 expression was significantly 
lower in patients with a positive local culture or negative 
cultures than in those with a positive blood culture, 
findings that support those of the report.18 These results 
were similar to those of CRP and PCT, two conventional 
infection markers, and all three markers showed similar 
positive rates regardless of culture results. Based on 
these results, CD64 seemed to have similar utility as 
conventional infection markers regardless of whether 
infection was systemic or local.
 Antibiotic administration before CD64 measurement 
was shown to decrease the sensitivity and specificity of 
CD64 as an infection marker.15 In our study, the positive 
rate of each infection marker was similar between the 
antibiotic and no-antibiotic groups. However, no patients 
in the positive blood culture group received antibiotics 
before CD64 measurement. The ratios of patients who 
received antibiotics were different among groups, and 
this might have influenced our results.
 Regarding the timing of CD64 assessment, patients 
in whom CD64 was measured later than 7 days after 
infection onset showed significantly lower CD64 values 
than patients in whom CD64 was measured within 
7 days. Cid et al. demonstrated that CD64 increased 
within 24 hours after infection onset, began to decrease 
48 hours later, and reached baseline levels within 7 
days.16 Therefore, the diagnostic sensitivity of CD64 is 
decreased in chronic infection.13 Conventional infection 
markers show a similar temporal relation to infection 
onset. In our study, the positive rate of CD64 was lower 
within 7 days than afterward, but there was no differ-
ence in CRP or PCT.
 CD64 levels were unaffected by immunodeficiency, 
and there were no significant differences in the positive 
rates of any of the three markers. Gros et al. indicated 
that the diagnostic sensitivity of CD64 was decreased 
in patients in the intensive care unit with poor overall 
clinical status.18 Therefore, it was expected that CD64 
levels would be decreased in immunodeficient patients, 
but this was not observed in our study. However, our 
results may have been influenced by the fact that there 
were different percentages of immunodeficient patients 
in the three infection status groups: 79% (five patients) 
in the positive blood culture group, 56% (seven patients) 
in the positive local culture group, and 56% (11 patients) 
in the culture-negative group. 
 We showed that the utility of CD64 was equivalent 
to conventional infection markers in patients with a vari-
ety of conditions. However, there are several challenges 
to routinely using CD64 in clinical settings. First, mea-
surement of CD64 expression on neutrophils requires 
flow cytometry and takes approximately 2 hours. Matsui 
et al. reported that measurements remained stable for 
at least 24 hours after blood samples were obtained.4 
While this issue was not statistically evaluated in this 
study, measurement values tended to decrease several 
hours after sampling, and it may therefore be necessary 
to measure CD64 levels immediately. Second, the cost 
of this measurement is not currently covered by health 
insurance in Japan. Third, measurement of CD64 is 
more complicated and time-consuming than the evalua-
tion of conventional markers, and there are many issues 
that must be resolved before CD64 assessment can 
replace standard tests. 
 There were several limitations to this study. The 
small sample size contributed to significant variation 
between groups, particularly regarding antibiotic ad-
ministration and timing of CD64 measurement, and 
this might have reduced the reliability of the results. 
In addition, the reason for the diagnosis of infection in 
culture-negative patients differed in each case, and a 
clear criterion should have been established instead.
 In conclusion, we evaluated the utility and efficacy 
of neutrophil CD64 expression in diagnosing muscu-
loskeletal infection. Several previous studies reported 
that CD64 was useful in diagnosing infection in patients 
with RA and those in the early post-surgical phase. 
Nevertheless, to the best of our knowledge, this is the 
first study to evaluate the utility of CD64 in musculo-
skeletal infection. It revealed that CD64 had equivalent 
diagnostic utility as conventional infection markers in 
various musculoskeletal infections.
The authors declare no conflict of interest.
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